Literature DB >> 26453584

Investigation of Skin Barrier Functions and Allergic Sensitization in Patients with Hyper-IgE Syndrome.

Gábor Mócsai1,2, Krisztián Gáspár1,2, Zsolt Dajnoki1,2, Beáta Tóth3, Edit Gyimesi4, Tamás Bíró5, László Maródi3, Andrea Szegedi6,7.   

Abstract

PURPOSE: Hyper-IgE syndrome (HIES) is a severe primary immunodeficiency, characterized by increased serum IgE levels as well as recurrent infections and atopic dermatitis (AD)-like skin lesions. AD is a chronic inflammatory skin disease with immunologic alterations (Th2-Th22 polarization) and characteristic skin barrier dysfunctions. Our aim was to investigate physicochemical skin barrier alterations and allergic sensitization in STAT3-HIES patients in order to explore whether skin barrier dysfunction can play a role in the eczematoid skin lesions in these patients.
METHODS: In our experiments STAT3 and FLG mutation analyses were performed in STAT3-HIES (n = 7) and AD (n = 49) patients. Laboratory parameters (LDH and Eos counts), immunologic alterations (Th17 cell counts), allergic sensitization (total and specific IgE levels, skin prick tests, and medical history records), skin barrier changes [transepidermal water loss (TEWL), skin pH], serum and stratum corneum thymic stromal lymphopoietin (TSLP) levels were also examined.
RESULTS: Impaired Th17 cell numbers, but normal physicochemical barrier functions, as well as serum and stratum corneum TSLP levels, were found in STAT3-HIES, while these parameters were significantly altered in AD patients. Allergic sensitization was detected in nearly all AD patients, while no signs of sensitization occurred in STAT3-HIES.
CONCLUSIONS: Our study demonstrated that the skin barrier functions of STAT3-HIES patients are not damaged and they differ significantly from the altered skin barrier functions of AD patients. A well-functioning physicochemical skin barrier may be one of the explanations on the contradiction between the extremely high total IgE levels and the lack of allergic sensitization in these patients. Our study underlines the importance of skin barrier in the development of allergic sensitization.

Entities:  

Keywords:  Atopic dermatitis; filaggrin; hyper-IgE syndrome; skin barrier

Mesh:

Substances:

Year:  2015        PMID: 26453584     DOI: 10.1007/s10875-015-0200-2

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  41 in total

Review 1.  The acidic milieu of the horny layer: new findings on the physiology and pathophysiology of skin pH.

Authors:  Frank Rippke; Volker Schreiner; Hans-Joachim Schwanitz
Journal:  Am J Clin Dermatol       Date:  2002       Impact factor: 7.403

Review 2.  [Significance of skin surface pH].

Authors:  G Yosipovitch; H I Maibach
Journal:  Harefuah       Date:  1996-04-01

Review 3.  Cutaneous manifestations of Hyper IgE syndrome.

Authors:  Yoshiyuki Minegishi; Masako Saito
Journal:  Allergol Int       Date:  2012-03-25       Impact factor: 5.836

4.  Filaggrin in the frontline: role in skin barrier function and disease.

Authors:  Aileen Sandilands; Calum Sutherland; Alan D Irvine; W H Irwin McLean
Journal:  J Cell Sci       Date:  2009-05-01       Impact factor: 5.285

5.  Thymic stromal lymphopoietin expression is increased in the horny layer of patients with atopic dermatitis.

Authors:  Y Sano; K Masuda; R Tamagawa-Mineoka; H Matsunaka; Y Murakami; R Yamashita; E Morita; N Katoh
Journal:  Clin Exp Immunol       Date:  2013-03       Impact factor: 4.330

Review 6.  Stratum corneum pH in atopic dermatitis: impact on skin barrier function and colonization with Staphylococcus Aureus.

Authors:  Frank Rippke; Volker Schreiner; Thomas Doering; Howard I Maibach
Journal:  Am J Clin Dermatol       Date:  2004       Impact factor: 7.403

7.  Diminished allergic disease in patients with STAT3 mutations reveals a role for STAT3 signaling in mast cell degranulation.

Authors:  Andrea M Siegel; Kelly D Stone; Glenn Cruse; Monica G Lawrence; Ana Olivera; Mi-yeon Jung; John S Barber; Alexandra F Freeman; Steven M Holland; Michelle O'Brien; Nina Jones; Celeste G Nelson; Laura B Wisch; Heidi H Kong; Avanti Desai; Orly Farber; Alasdair M Gilfillan; Juan Rivera; Joshua D Milner
Journal:  J Allergy Clin Immunol       Date:  2013-11-01       Impact factor: 10.793

Review 8.  Atopic dermatitis: a disease of altered skin barrier and immune dysregulation.

Authors:  Mark Boguniewicz; Donald Y M Leung
Journal:  Immunol Rev       Date:  2011-07       Impact factor: 12.988

9.  Defective IL-10 signaling in hyper-IgE syndrome results in impaired generation of tolerogenic dendritic cells and induced regulatory T cells.

Authors:  Masako Saito; Masayuki Nagasawa; Hidetoshi Takada; Toshiro Hara; Shigeru Tsuchiya; Kazunaga Agematsu; Masafumi Yamada; Nobuaki Kawamura; Tadashi Ariga; Ikuya Tsuge; Shigeaki Nonoyama; Hajime Karasuyama; Yoshiyuki Minegishi
Journal:  J Exp Med       Date:  2011-02-07       Impact factor: 14.307

10.  Claudin-based tight junctions are crucial for the mammalian epidermal barrier: a lesson from claudin-1-deficient mice.

Authors:  Mikio Furuse; Masaki Hata; Kyoko Furuse; Yoko Yoshida; Akinori Haratake; Yoshinobu Sugitani; Tetsuo Noda; Akiharu Kubo; Shoichiro Tsukita
Journal:  J Cell Biol       Date:  2002-03-11       Impact factor: 10.539

View more
  3 in total

1.  Detection of Antimicrobial Peptides in Stratum Corneum by Mass Spectrometry.

Authors:  Adrienn Jenei; Gergő Kalló; Zsolt Dajnoki; Krisztián Gáspár; Andrea Szegedi; Anikó Kapitány; Éva Csősz
Journal:  Int J Mol Sci       Date:  2021-04-19       Impact factor: 5.923

2.  Genetic polymorphisms in serine protease inhibitor Kazal-type 5 and risk of atopic dermatitis: A meta-analysis.

Authors:  Yunling Li; Yin Li; Wei Li; Xiaoxuan Guo; Sha Zhou; Huiwen Zheng
Journal:  Medicine (Baltimore)       Date:  2020-07-10       Impact factor: 1.817

3.  Hyper IgE in Childhood Eczema and Risk of Asthma in Chinese Children.

Authors:  Chantel Ng; Kam Lun Hon; Jeng Sum Charmaine Kung; Nga Hin Pong; Ting-Fan Leung; Chun Kwok Wong
Journal:  Molecules       Date:  2016-06-10       Impact factor: 4.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.